Clinical trials: Tamoxifen
Post Menopausal Women With Early Breast Cancer
Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)
Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire. Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).
- Trial name
- FAST (NCT01050634)
- Testing
- Aromasin (exemestane)
- Volunteers
- 980 people
- Sponsor
- Pfizer
Bipolar Disorder
Tamoxifen in Treatment of Acute Mania
Objective: Evidence indicates that the protein kinase C-PKC signaling cascade may be one of the direct targets in treatment of mania.
- Trial name
- NCT00411203
- Testing
- Tamoxifen Citrate
- Where
- Turkey (Türkiye)
- Volunteers
- 66 people
- Sponsor
- Stanley Medical Research Institute
Schizophrenia
Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women
The aim of the project is to assess the efficacy of Adjunctive Selective Estrogen Receptor Modulators (Raloxifene) on Negative and Cognitive symptoms of Schizophrenia in Postmenopausal Women.
- Trial name
- NCT03418831
- Testing
- Raloxifene Hydrochloride
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Mental Health Center
Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
This study aims to enroll premenopausal patients, with early breast cancer who are non-low-risk and hormone receptor-positive and have undergone prior surgical intervention at the Breast Cancer Center of Sun Yat-sen Memorial…
- Conditions
- Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk, Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen
- Trial name
- NCT05801705
- Testing
- Aromatase inhibitor, ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist), Tamoxifen
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Oocyte Recovery During Tamoxifen Adjuvant Therapy
Survival in young patients with cancer has increased and also have increased the adverse long-term side effects of chemotherapy, there is a large number of women who experience loss of ovarian function without accomplishing their…
- Trial name
- TAMOXIFERT (NCT02355600)
- Testing
- Oocyte retrieval
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Chronic Hepatitis C
Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
- Trial name
- NCT00749138
- Testing
- tamoxifen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Bader, Ted, M.D.
Breast Cancer
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer
The present study is a randomized open-label -phase III study that aims to compare the efficacy and safety of the adjuvant chemotherapy with simultaneous or sequential application of Zoladex up to 2-3 years for ≤ 45 year old…
- Trial name
- NCT01712893
- Testing
- Zoladex
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Fudan University
Breast Cancer
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy after surgery is effective in preventing a recurrence of ductal carcinoma in situ.
- Trial name
- NCT00077168
- Testing
- anastrozole, tamoxifen citrate, adjuvant therapy
- Where
- 29 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer Female
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer.
- Trial name
- POWER II (NCT06507618)
- Testing
- Tamoxifen, Letrozole, Anastrozole, or Exemestane
- Where
- 6 sites in United States
- Volunteers
- 354 people
- Sponsor
- University of Virginia
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen.
- Conditions
- Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- SOFT (NCT00066690)
- Testing
- Exemestane, Laboratory Biomarker Analysis, Oophorectomy
- Where
- 500 sites in United States, Canada and 1 more
- Volunteers
- 3,066 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Neoplasms
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2…
- Trial name
- EMBER-4 (NCT05514054)
- Testing
- Imlunestrant, Tamoxifen, Anastrozole
- Where
- 672 sites in United States, Argentina and 29 more
- Volunteers
- 8,000 people
- Sponsor
- Eli Lilly and Company
Desmoid Tumor
Toremifene in Treating Patients With Desmoid Tumors
RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using toremifene may fight the growth of desmoid tumors by reducing the production of estrogen.
- Trial name
- NCT00002595
- Testing
- toremifene, conventional surgery
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Advocate Lutheran General Hospital
Prostate Cancer, Erectile Dysfunction
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
The purpose of this study is to determine if a combination of neoadjuvant dutasteride and bicalutamide has the same efficacy and less toxicity than standard treatment with an LHRH agonist and bicalutamide for prostate…
- Conditions
- Prostate Cancer, Erectile Dysfunction, Lower Urinary Tract Symptoms
- Trial name
- NCT00866554
- Testing
- administration of a LHRH agonist and Bicalutamide, administration of Bicalutamide, Dutasteride and Tamoxifen
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- CHU de Quebec-Universite Laval
Breast Cancer
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer.
- Trial name
- NCT00004125
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the…
- Trial name
- e3 (NCT01674140)
- Testing
- anastrozole, everolimus, exemestane
- Where
- 1,458 sites in United States, Puerto Rico
- Volunteers
- 1,939 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women
The purpose of this study is to compare 5-year disease free survival rate (DFS rate) between the hormone receptor positive breast cancer patients who were added Goserelin to Tamoxifen for ovarian function suppression after…
- Trial name
- ASTRRA (NCT00912548)
- Testing
- goserelin, tamoxifen
- Where
- South Korea
- Volunteers
- 1,234 people
- Sponsor
- Korean Breast Cancer Study Group
Cyclic Breast Pain, Cyclic Mastalgia
Study of Afimoxifene Gel to Treat Cyclic Mastalgia in Premenopausal Women
The purpose of this study is to evaluate the efficacy of two doses of 4-hydroxy tamoxifen (4-OHT) compared with placebo on the intensity of cyclic mastalgia in pre-menopausal women with regular menstrual cycles who are not taking…
- Trial name
- NCT00272714
- Testing
- Afimoxifene (0.057%) in hydroalcoholic gel
- Volunteers
- 146 people
- Sponsor
- ASCEND Therapeutics
Breast Neoplasms, Venous Thromboembolism
Hemostatic Profiles of Endocrine Therapies for Breast Cancer
The aim of this prospective cohort study is to evaluate the modifications of the biological hemostatic profile associated with the use of endocrine therapy in women with breast cancer (tamoxifen or aromatase inhibitors).
- Trial name
- HEMOBREAST (NCT03381963)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Geneva
Breast Cancer
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
Men and post- or induced menopausal women with ER[+] and/or PgR[+], HER2[- ] advanced BC, with centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI) regimen.
- Trial name
- METALLICA (NCT04300790)
- Testing
- Alpelisib, Metformin, Fulvestrant
- Where
- 19 sites in Spain
- Volunteers
- 69 people
- Sponsor
- MedSIR
Breast Cancer
Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00009997
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- NYU Langone Health